| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CFP1; CGBP; SPP1; PCCX1; PHF18; hCGBP; ZCGPC1; HsT2645; 2410002I16Rik; 5830420C16Rik |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CXXC1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3条关于NEFH抗体的代表性文献摘要(基于公开研究领域整理，非真实文献，仅作示例)：
---
1. **文献名称**：*Neurofilament heavy chain as a biomarker in ALS cerebrospinal fluid*
**作者**：Smith J, et al.
**摘要**：研究分析了肌萎缩侧索硬化症(ALS)患者脑脊液中的NEFH蛋白水平，发现其浓度与疾病严重程度和进展速度显著相关，提示NEFH抗体检测可作为ALS病程监测的生物标志物。
2. **文献名称**：*Comparative analysis of neurofilament markers in neurodegenerative diseases*
**作者**：Johnson R, et al.
**摘要**：通过比较NEFH抗体与其他神经丝蛋白(如NEFL)的检测效能，发现NEFH在阿尔茨海默病和多发性硬化症患者血清中特异性升高，可能反映大直径轴突的损伤。
3. **文献名称**：*NEFH antibody validation in a rat spinal cord injury model*
**作者**：Lee S, et al.
**摘要**：研究验证了NEFH抗体在脊髓损伤大鼠模型中的标记效果，显示其在受损神经元中的强免疫反应性，支持其用于神经创伤后病理评估。
---
注：以上为模拟示例，实际文献需通过PubMed/Google Scholar等平台检索关键词(如"neurofilament heavy chain antibody"或"NEFH biomarker")获取。
The neurofilament heavy chain (NEFH) antibody is a critical tool in neuroscience research, targeting the heavy subunit of neurofilaments (NFs), which are major components of the neuronal cytoskeleton. Neurofilaments, comprising light (NEFL), medium (NEFM), and heavy (NEFH) chains, form intermediate filaments that maintain axonal structure, regulate diameter, and influence signal transduction. NEFH, the largest subunit (~200 kDa), contributes to filament stability and axonal caliber through its long carboxyl-terminal tail.
NEFH antibodies are widely used to study neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Charcot-Marie-Tooth disease, where neurofilament aggregation or mislocalization is observed. These antibodies enable detection of NEFH in tissues or biofluids via techniques like immunohistochemistry, Western blotting, or ELISA. Elevated neurofilament levels in cerebrospinal fluid (CSF) or blood, measured using NEFH-specific antibodies, are recognized biomarkers for neuronal injury, aiding disease monitoring and therapeutic evaluation.
Recent studies also explore NEFH antibodies in traumatic brain injury and multiple sclerosis, emphasizing their diagnostic and prognostic value. However, cross-reactivity with other neurofilament subunits or degradation products requires careful validation. Overall, NEFH antibodies remain indispensable for unraveling neurofilament biology and advancing neurological disorder research.
×
